SalioGen Therapeutics is a biotechnology company on a mission to accelerate the impact of genetic medicine for patients using its novel Gene Coding™ technology. Gene Coding is a non-viral method of integrating large or multiple whole genes into the genome at precise locations through transposition. This mechanism does not induce double-strand breaks or use guide RNA and has the potential to overcome the safety risks and limitations of other genetic medicine approaches.SalioGen's lead programs focus on one-time treatments for Stargardt disease and cystic fibrosis. The company is also developing its Gene Coding technology for additional indications, such as other inherited retinal diseases, and to engineer CAR-T cells for cancer and autoimmune conditions.